Therefore, investigating the potential of targeted drugs to downregulate PDLIM2 expression, specifically in triple-negative breast cancer patients, may aid the development of future therapeutic strategies against this cancer subtype. The gene discussed is PDLIM2; the disease is triple-negative breast carcinoma.